Navigation Links
Dendreon Reports Third Quarter 2008 Financial Results
Date:11/7/2008

SEATTLE, Nov. 7 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended September 30, 2008. Revenue for the third quarter of 2008 was $26,000 compared to $112,000 for the quarter ended September 30, 2007. Revenue for the nine months ended September 30, 2008 was $83,000 compared to $715,000 for the nine months ended September 30, 2007.

Dendreon's total operating expenses for the third quarter of 2008 were $17.3 million compared to $19.8 million in 2007. Dendreon's total operating expenses for the nine months ended September 30, 2008 were $55.1 million compared to $75.2 million for the same period in 2007.

The net loss for the quarter ended September 30, 2008 was $26.8 million, or $0.29 per share, compared to a net loss of $19.2 million, or $0.23 per share, for the quarter ended September 30, 2007. The net loss for the nine months ended September 30, 2008 was $62.8 million, or $0.71 per share, compared to $72.3 million, or $0.88 per share for the nine months ended September 30, 2007. Included in our net loss for the three and nine months ended September 30, 2008 was a non-cash charge of $9.1 million and $6.8 million, respectively, to other expense. This represents an increase in the fair value of the warrants issued in connection with our April 3, 2008 common stock offering, which has been recorded as a liability.

Cash, cash equivalents and short-term and long-term investments at September 30, 2008 totaled $106.6 million compared to $120.6 million at December 31, 2007. Additionally, subsequent to September 30, 2008, the Company received net proceeds of $19.8 million relating to a draw down on the Company's equity line of credit with Azimuth Opportunity Ltd.

Recent Highlights:

* Completed the planned interim analysis of the Phase 3, randomized,

double-blind, placebo-controlled IMPACT (IMmunotherapy for Prostate

AdenoCarcinoma Treatment, also know
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
2. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
5. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
6. Dendreon Reports First Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
8. Dendreon Announces Closing of Registered Direct Offering
9. Dendreon Announces $47 Million Registered Direct Offering
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on ... clinical safety assessment in biosimilars. , Regulatory frameworks ... for biosimilar drug development, however the complex nature ... regards to quality, safety and efficacy extremely challenging. ... development and registration, development strategies differ significantly from ...
(Date:1/15/2014)... 2014 DTS Language Services, Inc ... Online Web Portal for Life Science organizations who need ... to specify the subject matter of their documents in ... sub-domains. This will help reduce time-to-delivery of translations, often ... decrease the likelihood of error. , “All translations are ...
(Date:1/14/2014)... PA (PRWEB) January 14, 2014 Date: ... 11 p.m. , Location: Warrington Country Club, 1360 Almshouse ... B Foundation, the only national nonprofit organization solely dedicated ... the quality of life for those affected worldwide, will ... at Warrington Country Club in Warrington, Pa. , ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... has initiated coverage of Alliqua, Inc. (OTCQB: ALQA). ... manufacturing, and marketing proprietary products to serve the ... http://equitiesiq.com/reports/alliqua/ , In late 2012, Alliqua was ... which launched the company’s new strategy to become ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 27 th in the nation in its friendliness to ... & Entrepreneurship Council , which released its 10th annual rankings ... nonprofit small business advocacy group headquartered in Washington, D.C. , ... , author of the study, "The 'Small Business Survival ...
... More than 30 years ago, then-Gov. Pat Lucey ... and machinery from property taxes. It was a bipartisan ... even when hard times and foreign competition threatened. , ... technology gain a competitive toehold by reducing state ...
... - A group of private colleges and universities ... technology platform using systems of Jenzabar, Inc. ... agreement with the Wisconsin Association of Independent Colleges ... systems. Those include the Jenzabar EX ERP System, Jenzabar's ...
Cached Biology Technology:Modernizing the tax code can make Wisconsin tech businesses more competitive 2Modernizing the tax code can make Wisconsin tech businesses more competitive 3
(Date:3/12/2014)... basic recipe of life, and all cells have the ... Physiology at the Perelman School of Medicine, University of ... -- is necessary for wound healing, clotting, fetal development, ... On the other hand, cell movement can be deleterious ... to set up shop in other tissues during cancer ...
(Date:3/12/2014)... aggressive and painful form of tooth decay that frequently ... may result from a nefarious partnership between a bacterium ... of print in the journal Infection and Immunity ... so severe that treatment frequently requires surgeryin the operating ... University of Pennsylvania. , "Our data will certainly ...
(Date:3/12/2014)... make it easier for research teams comprised of ... Kingdom to manage funding logistics and to simultaneously ... by the U.S. National Science Foundation,s (NSF) Directorate ... Biological Sciences Research Council (BBSRC). , This ... process that will allow U.S./U.K. research teams to ...
Breaking Biology News(10 mins):Protein key to cell motility has implications for stopping cancer metastasis 2Bacterium and fungus team up to cause virulent tooth decay in toddlers 2New bilateral pilot opportunity will fund collaborations between US and UK bioscience researchers 2
... Scandinavian studies have provided further evidence that environmental ... The studies, published online today (Thursday 28 April) ... suggest that environmental pollutants could be changing the ... (sex determining) chromosomes and that they could be ...
... of researchers led by University of Illinois at Chicago professor ... in the United States later this century. , That prediction, ... among young people and minorities, is from a special report ... Journal of Medicine. , The study determines that obesity currently ...
... researchers, have identified a specific protein molecule that is ... infections, leading the way for development of future vaccines ... 28 issue of Science Express, the study provides insight ... system--a problem of great scientific and clinical importance. , ...
Cached Biology News:How the environment could be damaging men's reproductive health 2How the environment could be damaging men's reproductive health 3How the environment could be damaging men's reproductive health 4US life expectancy about to decline, researchers say 2US life expectancy about to decline, researchers say 3Yale researchers identify molecule for detecting parasitic infection in humans 2
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
...
... DEPC-treated Water is suitable ... is prepared by incubating with ... autoclaved to remove the DEPC.DNase/RNase-Free ... for use in all molecular ...
Biology Products: